# 1st Gen Model Biogen Idec Inc. Biological products, except diagnostic
- $280.57Last close price
at 22-jun-2017 -
Subscribe >>
Deal exit on
June 23, 2017 Deal entry on
June 23, 2017 - 5.70%Expected margin
- 53.33% successful of 60 deals
BIIB
Model's trade recommendations -0.43% Return for period
-4.83% Annual return
$59.51B Market Cap
β 0.83
BIIB
Model (following trade recommendations)BIIB
Underlying stockS&P 500
Index- STRONG BUY Analysts consensus recommendation
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Industry sector: Medical
Sector classification: Biological products, except diagnostic
Deep Learning based analysis and prediction model for Biogen Idec Inc. (BIIB) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 2, 2015.
Market data for BIIB model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 213M |
| P/E | 13.50 |
| Shares Outstanding | 214M |
| % Held by Insiders | 0.32% |
| % Held by Institutions | 87.39% |
| EPS (last reported FY) | $20.22 |
| EPS (last reported Q) | $5.20 |
| EPS, estimated (last reported Q) | $4.97 |
| Total revenues | $11 B |
| Net income | $4 B |